Biopharma News

Mar 29, 2017
The mAb is the first approved treatment that targets the progressive form of the disease.
Mar 28, 2017
By BioPharm International Editors
The company has signed two separate agreements with the Agency for Science, Technology, and Research (A*STAR) and the Nanyang Technological University (NTU) to progress its therapeutic stem cell pipeline.
Mar 28, 2017
FDA approved Dupixent for the treatment of atopic dermatitis amidst a preemptive lawsuit filed by Sanofi/Regeneron involving the drug and an Amgen patent covering IL-4 inhibitors.
Mar 27, 2017
By BioPharm International Editors
The Basel office will house the clinical development team and other functions to progress the company’s lead compound emapalumab.
Mar 24, 2017
The company said it plans to expand diabetes manufacturing facilities in the United States.
Mar 24, 2017
By BioPharm International Editors
FDA approved avelumab for the treatment of patients with Merkel cell carcinoma.
Mar 23, 2017
Sanofi and Regeneron are asking a federal court to issue a judgment of non-infringement for Amgen’s ‘487 patent.
Mar 20, 2017
By BioPharm International Editors
The companies will be expanding their collaboration to discover novel therapies that will include up to eight additional targets using CytomX’s proprietary Probody platform.
Mar 17, 2017
By BioPharm International Editors
The company said that it has successfully completed its first in-orbit experiment using its miniature end-to-end space laboratory.
Mar 14, 2017
By BioPharm International Editors
Under the agreement, Allergan will receive exclusive access to five of Editas’ ocular programs.
native1_300x100
lorem ipsum